METHODS FOR QUANTITATION OF HLA-DR AND CD11B

• Main Author: DAVIS, KENNETH, A
• Format: Patent
• Language: English; French
• Published: 30.11.2000
• Edition: 7
• Subjects: CHEMISTRY; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; TECHNICAL SUBJECTS COVERED BY FORMER USPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ARTCOLLECTIONS [XRACs] AND DIGESTS; TESTING

Improved methods, reagents, and kits for quantitation of HLA-DR and/or CD11b expression on peripheral blood cells are presented. Inclusion of a lysosomotropic amine, such as chloroquine, during staining stabilizes HLA-DR and CD11b expression. Use of a novel anti-CD14 conjugate, anti-CD14-PerCP/CY5.5, permits the ready discrimination of monocytes. The improved methods, reagents, and kits can be used to assess immune competence, and to direct and monitor immunostimulatory therapies in patients exhibiting monocyte deactivation. L'invention concerne des techniques, des réactifs et des kits améliorés permettant de quantifier l'expression de HLA-DR et/ou de CD11b sur les cellules du sang périphérique. L'inclusion, au cours de la coloration, d'une amine lysosomotropie, telle que la chloroquine, stabilise l'expression de HLA-DR et de CD11b. L'utilisation d'un nouveau conjugué anti-CD14, le PerCP/CY5.5 anti-CD14, permet une discrimination immédiate des monocytes. Les techniques, réactifs et kits améliorés de l'invention peuvent être utilisés afin d'évaluer l'immunocompétence ainsi que pour diriger et suivre des thérapies immunostimulatrices chez des patients chez lesquels les monocytes ne sont plus activés.